These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 17488751)

  • 21. Efficient management of rheumatoid arthritis significantly reduces long-term functional disability.
    Tanaka E; Mannalithara A; Inoue E; Hara M; Tomatsu T; Kamatani N; Singh G; Yamanaka H
    Ann Rheum Dis; 2008 Aug; 67(8):1153-8. PubMed ID: 17971459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The composite DAS Score is impractical to use in daily practice: evidence that physicians use the objective component of the DAS in decision making.
    Lindsay K; Ibrahim G; Sokoll K; Tripathi M; Melsom RD; Helliwell PS
    J Clin Rheumatol; 2009 Aug; 15(5):223-5. PubMed ID: 19590441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
    Carroll MB; Bond MI
    Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response.
    Pachot A; Arnaud B; Marrote H; Cazalis MA; Diasparra J; Gouraud A; Mougin B; Miossec P
    J Rheumatol; 2007 Nov; 34(11):2158-61. PubMed ID: 17896807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
    Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
    Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies.
    Kievit W; Fransen J; Adang EM; Kuper HH; Jansen TL; De Gendt CM; De Rooij DJ; Brus HL; van de Laar MA; Van Riel PC
    Ann Rheum Dis; 2009 Jun; 68(6):844-9. PubMed ID: 18625616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
    van der Pouw Kraan TC; Wijbrandts CA; van Baarsen LG; Rustenburg F; Baggen JM; Verweij CL; Tak PP
    Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy.
    Wolfe F; Michaud K
    J Rheumatol; 2007 Aug; 34(8):1674-83. PubMed ID: 17611989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects between good and poor clinical responders.
    La DT; Collins CE; Yang HT; Migone TS; Stohl W
    Ann Rheum Dis; 2008 Aug; 67(8):1132-8. PubMed ID: 17967830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
    Park MC; Chung SJ; Park YB; Lee SK
    Scand J Rheumatol; 2008; 37(3):173-8. PubMed ID: 18465450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
    Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
    Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade.
    Ingegnoli F; Fantini F; Favalli EG; Soldi A; Griffini S; Galbiati V; Meroni PL; Cugno M
    J Autoimmun; 2008 Sep; 31(2):175-9. PubMed ID: 18707846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
    van den Bemt BJ; den Broeder AA; Snijders GF; Hekster YA; van Riel PL; Benraad B; Wolbink GJ; van den Hoogen FH
    Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab therapy in rheumatoid arthritis in daily practice.
    Assous N; Gossec L; Dieudé P; Meyer O; Dougados M; Kahan A; Allanore Y
    J Rheumatol; 2008 Jan; 35(1):31-4. PubMed ID: 18176989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychometric properties of the Rheumatoid Arthritis Disease Activity Index (RADAI) in a cohort of consecutive Dutch patients with RA starting anti-tumour necrosis factor treatment.
    Veehof MM; ten Klooster PM; Taal E; van Riel PL; van de Laar MA
    Ann Rheum Dis; 2008 Jun; 67(6):789-93. PubMed ID: 17974597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Guidelines for the use of biologic therapies in rheumatoid arthritis--December 2006 update].
    Grupo de Estudos de Artrite Reumatóide (GEAR) da Sociedade Portuguesa de Reumatologia (SPR)
    Acta Reumatol Port; 2007; 32(1):37-41. PubMed ID: 17450763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eligibility of rheumatoid arthritis patients for anti-TNF-alpha therapy according to the 2005 recommendations of the French and British Societies for Rheumatology.
    Fautrel B; Flipo RM; Saraux A
    Rheumatology (Oxford); 2008 Nov; 47(11):1698-703. PubMed ID: 18794185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and histologic findings in patients with uveal melanomas after taking tumor necrosis factor-α inhibitors.
    Damento G; Kavoussi SC; Materin MA; Salomão DR; Quiram PA; Balasubramaniam S; Pulido JS
    Mayo Clin Proc; 2014 Nov; 89(11):1481-6. PubMed ID: 25444484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.